Indeed, Ogitani et al. revealed that T-DXd has the potential to deliver sufficient DXd into cancer cells regardless of HER2 levels, that is, T-DXd can inhibit cell proliferation of not only HER2-strong positive cells but also HER2-weak positive cells. This evidence concerns the gene ERBB2 and cancer.